Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06851559 · ClinicalTrials.gov registry record · Phase 2
A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
A Phase 2 study of Eosinophilic Esophagitis, sponsored by Phathom Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 20
- Study locations
NCT06851559: Recruiting Phase 2 study of Eosinophilic Esophagitis, sponsored by Phathom Pharmaceuticals.
NCT06851559 is a Phase 2 study of Eosinophilic Esophagitis that is actively recruiting participants, run by Phathom Pharmaceuticals. The registered enrollment target is 80 participants, below the 862-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06851559, a Phase 2 study of Eosinophilic Esophagitis, is actively recruiting participants, sponsored by Phathom Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to assess the efficacy of vonoprazan 20 mg once daily (QD) compared to placebo QD in the number of participants with a peak eosinophilic histologic response \<15 eosinophils per high-power field (eos/hpf) after 12 weeks of therapy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Vonoprazan
Study Locations (20)
Florida
- Nature Coast Clinical Research - Inverness
- Encore Borland-Groover Clinical Research - Jacksonville
- International Center for Research - Tampa
California
- GW Research, Inc - Chula Vista
- Southern California Research Institute Medical Group - Los Angeles
Colorado
- Rocky Mountain Gastroenterology - Lakewood
- Western States Clinical Research, Inc. - Wheat Ridge
Idaho
- Treasure Valley Medical Research - Boise
- Grand Teton Research Group - Idaho Falls
Illinois
- Northwestern Medicine Digestive Health Center - Chicago
- GI Alliance - Gurnee - Gurnee
Louisiana
- Combined Gastro, LLC - Lafayette
- Tandem Clinical Research GI, LLC - Marrero
Arkansas
- Preferred Research Partners, Inc - Little Rock
Connecticut
- Connecticut Clinical Research Institute - Bristol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-10-30 |
| Est. Completion | 2027-03 |
| Phase | Phase 2 |
What NCT06851559 shows while recruiting
NCT06851559 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 862-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Eosinophilic Esophagitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06851559 names 20 study sites across 13 states, led by Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06851559 about?
NCT06851559 is a clinical study titled "A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks". The primary objective of this study is to assess the efficacy of vonoprazan 20 mg once daily (QD) compared to placebo QD in the number of participants with a peak eosinophilic histologic response \<15 eosinophils per high-power field (eos/hpf) after 12 weeks of therapy.
What is the current status of trial NCT06851559?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2025-10-30. Estimated completion is 2027-03.
What conditions does trial NCT06851559 study?
This clinical trial studies the following conditions: Eosinophilic Esophagitis.
What interventions are being tested in trial NCT06851559?
The interventions under investigation include: Placebo (DRUG), Vonoprazan (DRUG).
Who is sponsoring clinical trial NCT06851559?
This trial is sponsored by Phathom Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06851559 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Esophagitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06851559's enrollment target sits among peer trials
80 23rd of 44 higher than 22 of 44 other Eosinophilic Esophagitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Eosinophilic Esophagitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE
RECRUITING · Phase 2
-
Zemaira Eosinophilic Esophagitis Pilot Study
RECRUITING · Phase 2
-
Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years
COMPLETED · Phase 2
-
A Study of Flovent in Patients With Eosinophilic Esophagitis
COMPLETED · Phase 2
-
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
COMPLETED · Phase 2
-
Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI